Trials / Withdrawn
WithdrawnNCT03499041
A Study of LY3314814 in Participants With Liver Impairment
Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3314814 | Administered orally |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2018-04-17
- Last updated
- 2018-06-28
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03499041. Inclusion in this directory is not an endorsement.